Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ascending multiple-dose PRM-151 in idiopathic pulmonary fibrosis
NL-OMON36629Active, not recruiting
- Sponsor
- Promedior
- Start
- May 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of zinpentraxin alfa in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Promedior. Primary endpoint: Safety and tolerability. Started May 2011; status: active, not recruiting.
02
Drugs
zinpentraxin alfa
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON36629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36629.